NextCell´s publication of the phase I/II clinical trial in type I diabetes accepted

NextCell Pharma AB (”NextCell” or ”Company”) have had their article detailing the results of their phase I/II clinical trial in type I diabetes accepted in the peer-reviewed journal Diabetologia.

NextCell Pharma AB is a cell therapy company working in the development and commercialization of the mesenchymal stromal cell therapy product, ProTrans. This product, with its proprietary platform technology, is in clinical development for the treatment of autoimmune conditions, such as type I diabetes and inflammatory conditions such as viral pneumonia.

NextCell´s seminal study in type 1 diabetes, with their advanced therapeutic medicinal product, ProTrans, has been accepted for publication in the journal Diabetologia. The article, entitled, “Umbilical Cord-Derived Mesenchymal Stromal Cells Preserve Endogenous Insulin Production in Type 1 Diabetes: a Phase I/II Double-blinded, Placebo-controlled, Randomized trial” details how a single infusion of ProTrans can maintain the endogenous production of insulin, slowing the progression of the disease.

“It is fantastic to have our first study in type I diabetes published. This study has been the foundation for our clinical development programme in type I diabetes. The study, although small, presents strong data indicative of the effectiveness of ProTrans treatment in slowing diabetic disease development. Based on these data we have moved forward with a pediatric study investigating the efficacy of our drug product in newly diagnosed type I diabetics in the 7-21 age range, ”says Dr Mathias Svahn, CEO for NextCell Pharma.

The data reported in the manuscript was generated in collaboration with Professor Per-Ola Carlsson, Principal Investigator at Uppsala University and Karolinska Trial Alliance, Karolinska University Hospital, Huddinge, Sweden(Clinicaltrials.gov identifier NCT03406585).

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO
Patrik Fagerholm, CFO

Tel:08-735 5595
E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

 LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

About NextCell Pharma AB

NextCell is a celltherapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5%of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍